177 related articles for article (PubMed ID: 24201083)
1. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
Qu X; Felder MA; Perez Horta Z; Sondel PM; Rakhmilevich AL
Int Immunopharmacol; 2013 Dec; 17(4):1141-7. PubMed ID: 24201083
[TBL] [Abstract][Full Text] [Related]
2. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.
Johnson EE; Buhtoiarov IN; Baldeshwiler MJ; Felder MA; Van Rooijen N; Sondel PM; Rakhmilevich AL
J Immunother; 2011 Jan; 34(1):76-84. PubMed ID: 21150715
[TBL] [Abstract][Full Text] [Related]
3. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
4. Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.
Shi Y; Felder MA; Sondel PM; Rakhmilevich AL
Mol Immunol; 2015 Aug; 66(2):208-15. PubMed ID: 25829245
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
Alderson KL; Luangrath M; Elsenheimer MM; Gillies SD; Navid F; Rakhmilevich AL; Sondel PM
Cancer Immunol Immunother; 2013 Apr; 62(4):665-75. PubMed ID: 23151945
[TBL] [Abstract][Full Text] [Related]
6. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
7. Optimized Gemcitabine Therapy in Combination with E7 Peptide Immunization Elicits Tumor Cure by Preventing Ag-Specific CTL Inhibition in Animals with Large Established Tumors.
Jang HY; Han BS; Kwon B; Sin JI
DNA Cell Biol; 2018 Oct; 37(10):850-860. PubMed ID: 30227079
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.
Buhtoiarov IN; Sondel PM; Wigginton JM; Buhtoiarova TN; Yanke EM; Mahvi DA; Rakhmilevich AL
Immunology; 2011 Feb; 132(2):226-39. PubMed ID: 21039467
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.
Rakhmilevich AL; Baldeshwiler MJ; Van De Voort TJ; Felder MA; Yang RK; Kalogriopoulos NA; Koslov DS; Van Rooijen N; Sondel PM
Cancer Immunol Immunother; 2012 Oct; 61(10):1683-97. PubMed ID: 22392192
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
Ghansah T; Vohra N; Kinney K; Weber A; Kodumudi K; Springett G; Sarnaik AA; Pilon-Thomas S
Cancer Immunol Immunother; 2013 Jun; 62(6):1083-91. PubMed ID: 23604104
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.
Van De Voort TJ; Felder MA; Yang RK; Sondel PM; Rakhmilevich AL
J Immunother; 2013 Jan; 36(1):29-40. PubMed ID: 23211623
[TBL] [Abstract][Full Text] [Related]
12. Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.
Tongu M; Harashima N; Tamada K; Chen L; Harada M
Cancer Sci; 2015 Jan; 106(1):9-17. PubMed ID: 25363339
[TBL] [Abstract][Full Text] [Related]
13. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
14. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Buhtoiarov IN; Lum H; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Immunol; 2005 May; 174(10):6013-22. PubMed ID: 15879094
[TBL] [Abstract][Full Text] [Related]
15. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
16. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
Rakhmilevich AL; Buhtoiarov IN; Malkovsky M; Sondel PM
Cancer Immunol Immunother; 2008 Aug; 57(8):1151-60. PubMed ID: 18214476
[TBL] [Abstract][Full Text] [Related]
17. Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6C
Wu C; Tan X; Hu X; Zhou M; Yan J; Ding C
J Immunol; 2020 Jan; 204(1):212-223. PubMed ID: 31776206
[TBL] [Abstract][Full Text] [Related]
18. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Lum HD; Buhtoiarov IN; Schmidt BE; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Leukoc Biol; 2006 Jun; 79(6):1181-92. PubMed ID: 16565324
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotides augment antitumor efficacy of folate receptor α based DNA vaccine.
Qiu Z; Xing L; Zhang X; Qiang X; Xu Y; Zhang M; Zhou Z; Zhang J; Zhang F; Wang M
Oncol Rep; 2017 Jun; 37(6):3441-3448. PubMed ID: 28498413
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
Pratesi G; Petrangolini G; Tortoreto M; Addis A; Belluco S; Rossini A; Selleri S; Rumio C; Menard S; Balsari A
Cancer Res; 2005 Jul; 65(14):6388-93. PubMed ID: 16024642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
